非奈利酮心血管获益的介导因素:UACR与收缩压
本研究基于FIDELITY汇总数据(n=12,143),采用因果中介分析,评估非奈利酮治疗4个月时UACR、收缩压、体重和血钾变化对长期心血管获益的中介作用。结果显示,UACR和收缩压分别介导39%和21%的心血管获益,联合介导50%,而体重和血钾无中介作用。
要点
- 非奈利酮早期降低UACR和收缩压,共同介导50%的长期心血管获益。
- UACR降低介导39%心血管获益,收缩压降低介导21%。
- 体重和血钾变化虽显著,但不介导心血管获益。
核心结论
- 在T2D合并CKD患者中,非奈利酮治疗4个月时UACR和收缩压的降低共同介导了50%的长期心血管获益。
- 体重和血钾变化不介导心血管获益,支持UACR和收缩压作为心血管疗效的互补指标。
研究设计与样本
- 基于FIDELITY汇总数据(FIDELIO-DKD和FIGARO-DKD,n=12,143)的因果中介分析。
- 中介变量为基线至第4个月的对数UACR、收缩压、体重和血钾变化;结局为第4个月至首次心血管事件时间。
- 采用Weibull参数加速失效时间回归模型,通过自举法估计UACR和收缩压的联合中介效应。
主要发现
- 第4个月时,非奈利酮降低UACR 32.2%(95%CI 30.3-34.2),降低收缩压3.6 mmHg(95%CI 3.1-4.1),降低体重0.23 kg(95%CI 0.13-0.32),升高血钾0.19 mEq/L(95%CI 0.17-0.20)。
- UACR介导39%(95%CI 7-71)的心血管获益,收缩压介导21%(95%CI 3-40);体重和血钾无中介作用。
- UACR和收缩压联合介导50%(95%CI 21-100)的心血管获益。
临床怎么用
- 在T2D合并CKD患者中,使用非奈利酮时早期监测UACR和收缩压下降,可作为评估长期心血管获益的指标。
局限性
- 本研究为基于FIDELITY数据的因果中介分析,中介效应估计的置信区间较宽,尤其联合中介效应上限达100%。
- 中介分析基于第4个月的变化,不能排除更早期或更晚期变化的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND HYPOTHESIS: Finerenone reduces cardiovascular events in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). The cardiovascular benefit emerges within months, before measurable kidney protection, but the early pathways carrying it are not comprehensively quantified. We hypothesized that early reductions in urine albumin-to-creatinine ratio (UACR) and systolic blood pressure (SBP) jointly mediate a substantial proportion of finerenone's long-term cardiovascular benefit, whereas changes in body weight and serum potassium do not. METHODS: We performed causal mediation analysis using individual patient data from FIDELITY (pooled FIDELIO-DKD and FIGARO-DKD; n = 12,143). Mediators were change from baseline to month 4 in log urine albumin-to-creatinine ratio (UACR), systolic blood pressure (SBP), body weight, and serum potassium. The outcome was time from month 4 to first cardiovascular event (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or heart failure hospitalization). Outcome models used parametric accelerated failure time regression with Weibull distribution. Joint mediation by UACR and SBP was estimated by bootstrapping. RESULTS: At month 4, finerenone reduced UACR by 32.2% (95% CI 30.3 to 34.2), SBP by 3.6 mmHg (3.1 to 4.1), and body weight by 0.23 kg (0.13 to 0.32), and increased serum potassium by 0.19 mEq/L (0.17 to 0.20). Although all four biomarkers changed significantly, only UACR and SBP mediated cardiovascular outcomes: UACR mediated 39% (95% CI 7 to 71) and SBP mediated 21% (3 to 40); body weight and potassium did not. Jointly, UACR and SBP mediated 50% (95% CI 21 to 100) of the cardiovascular benefit. CONCLUSIONS: In T2D and CKD, early reductions in UACR and SBP jointly account for half of finerenone's long-term cardiovascular benefit. Body weight and potassium changes do not mediate the benefit, supporting UACR and SBP as complementary indicators of cardiovascular efficacy.
引用
- Agarwal R, Pandey A, Solomon SD, et al. Systolic blood pressure and albuminuria reduction mediate cardiovascular benefits of finerenone in T2 diabetes and CKD. Nephrol Dial Transplant. 2026. PMID: 42360710. doi:10.1093/ndt/gfag150
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。